Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Wall Street Zen Upgrades Avalyn Pharma (NASDAQ:AVLN) to Hold
Avalyn Pharma (NASDAQ:AVLN - Get Free Report) was upgraded by research analysts at Wall Street Zen from a 'sell' rating to a 'hold' rating in a note issued to investors on Saturday, Wall Street Zen reports. AVLN has been the topic of several other…
Spyglass Pharma (NASDAQ:SGP) Price Target Raised to $45.00
Spyglass Pharma (NASDAQ:SGP - Get Free Report) had its price objective hoisted by research analysts at Citigroup from $42.00 to $45.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has a 'buy' rating on…
Royalty Pharma (NASDAQ:RPRX) Stock Rating Upgraded by Wall Street Zen
Royalty Pharma (NASDAQ:RPRX - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a 'buy' rating to a 'strong-buy' rating in a report issued on Saturday, Wall Street Zen reports. How Royalty Pharma Prints Cash Without…
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $91.00
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) had its target price raised by investment analysts at Morgan Stanley from $88.00 to $91.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has an 'overweight' rating on…
Royalty Pharma (NASDAQ:RPRX) Stock Rating Upgraded by Zacks Research
Royalty Pharma (NASDAQ:RPRX - Get Free Report) was upgraded by equities researchers at Zacks Research from a 'hold' rating to a 'strong-buy' rating in a research note issued to investors on Wednesday, Zacks reports. How Royalty Pharma Prints Cash…
Spyglass Pharma (NASDAQ:SGP) Stock Price Target Raised at Stifel Nicolaus
Spyglass Pharma (NASDAQ:SGP - Get Free Report) had its price objective upped by stock analysts at Stifel Nicolaus from $42.00 to $44.00 in a research note issued on Friday, Benzinga reports. The firm presently has a 'buy' rating on the stock.
Ascendis Pharma A/S's (ASND) 'Outperform' Rating Reaffirmed at Royal Bank Of Canada
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report)'s stock had its 'outperform' rating reaffirmed by stock analysts at Royal Bank Of Canada in a report issued on Friday, Benzinga reports. They currently have a $290.00 target price on the…
Ascendis Pharma A/S (NASDAQ:ASND) Given New $315.00 Price Target at UBS Group
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price target hoisted by research analysts at UBS Group from $269.00 to $315.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has a 'buy' rating on the…
Ascendis Pharma A/S (NASDAQ:ASND) Given New $352.00 Price Target at TD Cowen
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its target price lifted by stock analysts at TD Cowen from $341.00 to $352.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has a 'buy' rating on the…
Ascendis Pharma A/S (NASDAQ:ASND) Given New $315.00 Price Target at Cantor Fitzgerald
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price target upped by investment analysts at Cantor Fitzgerald from $300.00 to $315.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has an 'overweight'…
HC Wainwright Has Lowered Expectations for Ascendis Pharma A/S (NASDAQ:ASND) Stock Price
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price objective dropped by HC Wainwright from $344.00 to $335.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has a 'buy' rating on the biotechnology…
Canaccord Genuity Group Issues Positive Forecast for Ascendis Pharma A/S (NASDAQ:ASND) Stock Price
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price target upped by analysts at Canaccord Genuity Group from $268.00 to $274.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has a 'hold'…
Why Community Oncology Data Is A Blind Spot In Precision Medicine
Jason Baroff, Managing Partner – Ascend Technologies Group and MiBA Analytics. Precision oncology runs on a simple promise: The right test leads to the right therapy for the right patient. Over the past decade, I've seen many…
Exagen: Q3 Raises Questions About The Turnaround (Rating Downgrade)
Exagen is downgraded to Hold as Q3 results reveal slower revenue growth, weaker margins, and higher operating losses, clouding the turnaround outlook. XGN's Q3 revenue grew 7% year-over-year but declined 8% sequentially, with gross margin slipping…
F5: 4 Years Of EPS Growth And A Critical Role In The AI Era
Albert Anthony is the pen name of a business author on Amazon and a contributing analyst to investing platforms like Seeking Alpha since 2023, where he has over + 2,000 followers and has covered hundreds of stocks in multiple sectors including…
Receive a Daily briefing on Pharma Industry News
Get Started